Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Injection site reaction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    146 result(s) found for: Injection site reaction. Displaying page 4 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2015-000500-26 Sponsor Protocol Number: 01-1-101 Start Date*: Information not available in EudraCT
    Sponsor Name:Rapidscan Pharma Solutions EU Ltd (RPS EU Ltd)
    Full Title: An Open-label, Single Ascending-dose, Pharmacokinetic and Safety Study of Regadenoson (Rapidscan®) in Paediatric Patients with Cardiovascular Conditions and Diseases
    Medical condition: Regadenoson will be used as a pharmacologic stress agent in paediatric patients with cardiovascular problems, undergoing a clinically indicated myocardial perfusion MRI
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10065141 Vascular diagnostic procedure LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-001585-42 Sponsor Protocol Number: CA209-8KX Start Date*: 2019-01-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy
    Medical condition: The study population will include participants with 1 of the following advanced or metastatic tumors approved for treatment with nivolumab monotherapy: non-small cell lung cancer (NSCLC); renal ce...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027481 Metastatic melanoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002011-26 Sponsor Protocol Number: GP15-302 Start Date*: 2013-06-25
    Sponsor Name:Hexal AG
    Full Title: A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate t...
    Medical condition: moderate to severe chronic plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) CZ (Completed) GB (Completed) EE (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000984-15 Sponsor Protocol Number: PQBirch204 Start Date*: 2015-07-13
    Sponsor Name:Allergy Therapeutics (UK) Ltd
    Full Title: A multi-centre, double-blind, placebo-controlled study to explore the safety and efficacy of Birch Modified Allergen Tyrosine adsorbed + MPL (POLLINEX® Quattro Plus 1.0 mL Birch [PQ Birch]) in subj...
    Medical condition: Seasonal allergic rhinoconjunctivitis due to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002636-31 Sponsor Protocol Number: APHP211034 Start Date*: 2022-09-15
    Sponsor Name:Assistance Publique Hôpitaux de Paris/DRCI
    Full Title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the in...
    Medical condition: severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006447-95 Sponsor Protocol Number: CDX0159-07 Start Date*: 2022-09-09
    Sponsor Name:Celldex Therapeutics
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX-0159 in Patients with Chronic Inducible Urticaria
    Medical condition: Chronic Inducible Urticaria
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004858 10012499 Dermatographic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) LT (Trial now transitioned) HU (Trial now transitioned) LV (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005647-14 Sponsor Protocol Number: 07/cmc/4088e Start Date*: 2009-03-16
    Sponsor Name:Cardiff University
    Full Title: Gamma Delta T Cells and their role in the acute phase reaction to intravenous bisphosphonates
    Medical condition: Patients with osteoporosis or Paget's disease of bone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    9.1 10033362 Paget's disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003984-37 Sponsor Protocol Number: CMX001-211 Start Date*: 2018-07-30
    Sponsor Name:Chimerix, Inc
    Full Title: A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients with Adenovirus Viremia
    Medical condition: Treatment of adenovirus infections in adult allogeneic hematopoietic cell transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000434-21 Sponsor Protocol Number: PRT-PEG-15-10880 Start Date*: 2016-11-14
    Sponsor Name:Biogen Portugal
    Full Title: PLENO – Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current...
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002222-46 Sponsor Protocol Number: 36688 Start Date*: 2013-09-04
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human - VECTOR-II study A randomized controlled pilot study
    Medical condition: Inflammation, SIRS and endotoxemia
    Disease: Version SOC Term Classification Code Term Level
    15.1 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    15.1 10021881 - Infections and infestations 10060412 Septicaemia due to Escherichia coli (E. coli) LLT
    15.1 100000004848 10051553 Complement factor C1 LLT
    15.1 10021881 - Infections and infestations 10040047 Sepsis PT
    15.1 10018065 - General disorders and administration site conditions 10062357 SIRS LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000149-42 Sponsor Protocol Number: SYN008-002 Start Date*: 2021-08-16
    Sponsor Name:Synermore Biologics Co., Ltd
    Full Title: A Phase 3, Randomized, Double-blind, Parallel group, Active Controlled Study to Compare the Efficacy and Safety of SYN008 to Xolair® in Adult Patients with Chronic Spontaneous Urticaria and Inadequ...
    Medical condition: Chronic spontaneous urticaria (Allergic asthma, Chronic rhinosinusitis with nasal polyps)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001918-25 Sponsor Protocol Number: 111714 Start Date*: 2009-01-15
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open Phase I/II study of immunization with the recMAGE-A3 + AS15 Antigen Specific Cancer Immunotherapeutic in association with dacarbazine in patients with MAGE-A3 positive unresectable and prog...
    Medical condition: Patients with unresectable and progressive metastatic cutaneous melanoma, whose tumor expresses MAGE-A3.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003652-32 Sponsor Protocol Number: ISA101b-OPC-03-19 Start Date*: 2021-04-13
    Sponsor Name:ISA Therapeutics B.V.
    Full Title: A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16- positive Oropharyngeal Cancer who have experienced disease progres...
    Medical condition: Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031098 Oropharyngeal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005400-28 Sponsor Protocol Number: AL1502AV Start Date*: 2016-06-20
    Sponsor Name:Allergopharma GmbH & Co. KG
    Full Title: Open label phase II multicenter clinical trial to evaluate safety during accelerated dose escalation of an allergoid birch pollen preparation in patients with IgE mediated allergic rhinitis or rhin...
    Medical condition: Patients with seasonal rhinitis or rhinoconjunctivitis with or without controlled asthma during the birch pollen season
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10039776 Seasonal allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004108-16 Sponsor Protocol Number: HOFATA_v3.0 Start Date*: 2022-04-21
    Sponsor Name:Medical University Vienna
    Full Title: Host factors predicting target site concentration of antibiotics in critically ill patients: An explorative pharmacokinetic biomarker study
    Medical condition: All patients given standard of care intravenous therapy of the studied antibiotics will be screened against the inclusion criteria. Two groups are included: Group A (septic patients with organ dysf...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003278-42 Sponsor Protocol Number: TV48125-CNS-30056 Start Date*: 2017-07-10
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of T...
    Medical condition: Episodic Cluster headache (ECH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Completed) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003171-21 Sponsor Protocol Number: TV48125-CNS-30057 Start Date*: 2017-07-14
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of T...
    Medical condition: Chronic Cluster headache (CCH)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023830-22 Sponsor Protocol Number: AAG-G-H-1102 Start Date*: 2012-05-23
    Sponsor Name:TETEC AG
    Full Title: NDisc Study: A Prospective Randomized Multicentre Phase I / II Clinical Trial to Evaluate Safety and Efficacy of NOVOCART® Disc plus Autologous Disc Chondrocyte Transplantation (ADCT) in the Treatm...
    Medical condition: The subject has a disc herniation with back and /or leg pain (radicular pain) and an identification for sequestrectomy according to the guidelines of DGNC and DGOOC.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10022634 Intervertebral disc disorders LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001333-88 Sponsor Protocol Number: FP01C-17-001 Start Date*: 2017-08-23
    Sponsor Name:Foresee Pharmaceuticals Co., Ltd.
    Full Title: An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects with Prostate Cancer
    Medical condition: Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: LT (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-003277-22 Sponsor Protocol Number: FIL_FOLL19 Start Date*: 2021-10-04
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymphoma. A randomized, open label, phase III study by Fondazi...
    Medical condition: High tumor burden Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004864 10080213 In situ follicular lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 17:46:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA